Comparative Pharmacology
Head-to-head clinical analysis: ROMIDEPSIN versus ZOLINZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROMIDEPSIN versus ZOLINZA.
ROMIDEPSIN vs ZOLINZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Romidepsin is a histone deacetylase (HDAC) inhibitor that inhibits HDAC1 and HDAC2, leading to accumulation of acetylated histones and other proteins, resulting in cell cycle arrest and apoptosis in malignant cells.
Histone deacetylase (HDAC) inhibitor; inhibits class I and II HDAC enzymes, leading to accumulation of acetylated histones and non-histone proteins, inducing cell cycle arrest and apoptosis in malignant cells.
14 mg/m2 intravenously over 4 hours on days 1, 8, and 15 of a 28-day cycle.
400 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 1–5 hours), supporting continuous infusion or repeated dosing schedules.
Clinical Note
moderateRomidepsin + Digoxin
"Romidepsin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateRomidepsin + Digitoxin
"Romidepsin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRomidepsin + Deslanoside
"Romidepsin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRomidepsin + Acetyldigitoxin
"Romidepsin may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is approximately 2 hours. Due to its short half-life, vorinostat requires twice-daily dosing to maintain therapeutic concentrations.
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Biliary/fecal excretion accounts for ~25% of total clearance.
Zolinza (vorinostat) is primarily metabolized via glucuronidation and hydrolysis; renal excretion of unchanged drug is minimal (<1%). Approximately 52% of the dose is recovered in urine as metabolites, and about 43% in feces as metabolites and parent drug.
Category C
Category C
Histone Deacetylase Inhibitor
Histone Deacetylase Inhibitor